Obesitytirzepatideliraglutidephentermine
…ction may be indicated to achieve greater therapeutic benefit B.Obesity is a heterogeneous disease with varying effects on health, nece…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 1 of 2459rifampicinisoniazidisoniazidCImoxifloxacinlevofloxacinbedaquiline
…s introduced, initially referring to TB resistant to isoniazid, rifampicin, and at least three of the six main classes of second line drug…
Pulmonary fibrosisidiopathic pulmonary fibrosispirfenidone
…ities, and early integration of palliative care.Pathophysiology Pulmonary fibrosis involves a complex interplay between host and environment, refl…
MASLDsemaglutidesurvodutide
…, monitoring, and treatment needs to be established. Given that MASLD is a multisystem disease, assessing cost effectiveness should c…
obesitytype two diabetes
…esity and overweight. Among adults with a non-Asian background, obesity should be diagnosed if waist circumference is ≥88 cm in women o…
valrubicinpembrolizumabNMIBCnadofaragene firadenovecDurvalumab
…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…
nivolumabbrentuximab vedotinYale Universityurothelial carcinomaBreast cancer6melanomaleukaemia
…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…
nivolumabpembrolizumab
…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…
semaglutideSGLT2iType 2 diabetesliraglutide
…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…
ZykadiaCyramzaFruzaqlaFruquintinibImfinzidurvalumabramucirumabBrigatinibceritinib
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
COVID-19metformintype 2 diabeteschronic kidney diseasecoronary artery disease
…r associated risk of CV events among those testing positive for COVID-19.…
pembrolizumabbortezomibcrizotinibpembrolizumab35sunitinibdasatinib
…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …